I was counting pills into a vial one afternoon when the pharmacy owner walked past, letting out an exasperated sigh that said everything without saying a word. A patient had just called because her insulin copay had gone up again, same dose, same pharmacy, same insurance... and she was asking whether she should skip doses to stretch her supply.

I looked at my owner. She looked at me. And we both knew we'd had this same conversation at least ten times that week.

That moment stuck with me for years. Not because it was unique, but because it was so normal. Behind the counter, these questions carried a weight I'll never forget. We’re the ones standing face-to-face with patients when they hit a wall they don’t understand and don’t know how to navigate. And for too long, the pharmacy benefit managers (PBMs) who sit between patients, insurers, and us have been building that wall taller.

On February 4, 2026, the Federal Trade Commission secured a landmark settlement with Express Scripts and its affiliates. And I'm going to be honest with you: this is the most significant PBM enforcement action in US history. But before you celebrate and order the champagne, we need to talk about what this actually means for you, what it doesn't fix, and most importantly, what you need to do right now to make sure you're not just waiting for someone else's solution to land in your lap.

Here's the truth I want us to say out loud together: this settlement is a win. But it's a starting line, not a finish line.

What the Settlement Actually Does (and Why the Legalese Matters)

Let me translate the federal language into pharmacy language. Because the FTC settlement with Express Scripts contains provisions that directly affect how you get paid, what drugs you stock, and what your patients can afford. It's not abstract policy. It's your counter.

The Express Scripts settlement requires the company to stop a practice called "spread pricing," where PBMs favor higher-priced drugs over identical lower-cost versions, keeping the margin for themselves while charging patients higher copays. Imagine a scenario where generic atorvastatin 20mg and brand-name atorvastatin 20mg are therapeutically identical, but the generic is 30 cents and the brand is $8. Under old behavior, Express Scripts might push the brand to patients, pay themselves the spread, and the patient hits their copay based on the brand price. The settlement says: stop.

The settlement also requires Express Scripts to offer plan sponsors new options for structuring patient out-of-pocket costs based on net prices, not list prices. What that means in plain English: the games where list price gets inflated so copays stay high even when the actual drug cost is lower... those games have new guardrails.

Another huge one: the settlement requires that manufacturer compensation be delinked from drug list prices. PBMs used to be able to tier drugs based on rebate relationships rather than clinical value or cost. Now there's enforcement around actually separating those decisions. It's not perfect, but it moves the needle.

For insulin patients specifically, this settlement expands access to manufacturer affordability programs and caps what patients pay out of pocket for insulin. The settlement projects this will reduce patient OOP costs for insulin by up to $7 billion over 10 years. That's not just policy. That's our patient deciding she doesn't need to choose between insulin and rent.

And here's the provision that should get your attention: Express Scripts is transitioning to reimbursing standard community pharmacy claims based on actual acquisition cost plus a defined dispensing fee. This is what independent pharmacies have been asking for, for years. This is economics that actually works for independent operators. No more rebate games. No more trying to predict what the "usual and customary" price will be based on a secret formula controlled by someone else.

The settlement also reshores Ascent, a group purchasing organization with over $750 billion in annual purchasing activity, from Switzerland back to the United States. That matters for pharmacy procurement, compliance, and leverage. You're working in a system where supply chain gets more transparent and more grounded in US operations.

Transparency requirements have teeth now. Drug-level reporting to plan sponsors. Broker payment disclosures. The information asymmetry that PBMs have been exploiting starts to balance out.

The Acquisition-Cost-Plus-Dispensing-Fee Model: Finally, Economics That Make Sense

I want to spend time here because this is where theory becomes your quarterly P&L.

Years of counting pills taught me something fundamental: independent pharmacies have been trying to compete in a reimbursement model designed to advantage chain operations and PBM-owned pharmacies. You're dispensing the same pill, same day, same quality, but your margin structure is different. Sometimes you're reimbursed below acquisition cost on certain drugs. Sometimes the margin variation from one claim to the next is so wide you can't predict your cash flow. You're practicing at the top of your license, and the system is paying you like you're punching numbers into a register.

Acquisition-cost-plus-dispensing-fee changes that math. If acquisition cost is what you actually paid for the drug, and dispensing fee is the standard payment for your expertise, technology, and patient counseling, then the economics become predictable. You can plan. You can staff appropriately. You can invest in technology because you know what your reimbursement actually is.

This isn't fantasy. This is how pharmacy reimbursement works in other countries. This is how it works in mail order. And now, with this settlement, the model is moving toward independent community pharmacy.

But here's the micro-adjustment you need to make: don't assume this happens overnight. Express Scripts settling doesn't mean Cigna, Aetna, and United are rushing to adopt the same model tomorrow. The settlement creates precedent and pressure, but it doesn't automatically flatten the landscape.

What you do right now matters.

What About Insulin, and What About Your Diabetes Patients

One of the least sexy but most human-centered provisions in this settlement is the insulin affordability piece. The settlement expands patient access to manufacturer copay assistance programs and sets out-of-pocket cost caps that are lower than they were. For a patient with Type 2 diabetes on insulin, this potentially means the difference between accessing their medication and rationing doses.

For your pharmacy, this means:

• Your patients are more likely to fill prescriptions at full dose

• Your fill frequency becomes more predictable

• You have more conversations about adherence and outcomes instead of cost barriers

• Your pharmacy becomes a place where medication access improves

This is where innovation meets patient care. Because better reimbursement structure and lower patient copays create conditions where your role expands from "drug vending" to "outcome optimization." You get to ask the questions. How's the glucose meter working? Did you join a diabetes education program? Are you missing doses? And you get to partner on actual answers instead of deflecting to cost.

If you're not already exploring diabetes self-management education (DSME) programs or virtual diabetes prevention programs in your pharmacy, this settlement is a catalyst to start. More insulin access plus better education equals revenue, outcomes, and patients you're actually helping.

What Independents Should Do Right Now: Don't Wait for Trickle-Down

Here's what I know about waiting for policy to trickle down into practice: it's usually a slow leak. And in the meantime, other people are building advantage.

The most important move you can make right now is to diversify your sourcing and your strategy so you're not dependent on any single PBM to treat you fairly. This doesn't mean rejecting Express Scripts plans (although I know some very happy pharmacy owners who have). It means building leverage that makes you less vulnerable to the next unfair reimbursement model.

RxPost, to be direct, is exactly this kind of strategic move. When you're sourcing surplus inventory through a pharmacy-to-pharmacy marketplace that's DSCSA-compliant and transparent, you have acquisition cost advantage that doesn't depend on PBM generosity. You're recovering $60,800 in surplus value on average in your first 60 days. You're sourcing at 21.8% average discount versus WAC. That's not waiting. That's building your own advantage right now.

Second, audit your current contracts against the settlement requirements. Are your plans already moving toward acquisition cost plus dispensing fee? If not, have the conversation now instead of waiting. The settlement creates leverage for this negotiation. Use it.

Third, if you're not already doing it, start building the clinical service infrastructure that lets you capture revenue from patient care, not just from dispensing volume. Medication therapy management (MTM), DSME, vaccination programs, chronic disease management. The post-settlement pharmacy is one where reimbursement for knowledge and clinical judgment becomes more available because the raw dispensing margin becomes more stable.

Fourth, get compliant and stay visible on DSCSA tracing, DEA registration, and all the regulatory requirements that the new PBM landscape is going to scrutinize more carefully. Transparency is coming. Make it your advantage, not your vulnerability.

This is Where Innovation Meets Changing Regulatory Landscape

The PBM settlement is significant because it's the biggest regulatory enforcement action in the history of the industry. And it sets precedent. Other PBMs are now under scrutiny, patients are more aware of their rights, and the pharmacy industry is being invited to claim the role we should have had all along: the most trusted clinician in patients' lives, not a pinch point in a supply chain.

But don't wait for the precedent to trickle. Build your own advantage now. Diversify your sourcing. Build clinical services. Negotiate from a position of strength, not fear.

The settlement gets us closer to "profit and patients" alignment instead of profit being the only thing that matters to someone three layers removed from care. And for independent pharmacy, that changes everything.

Ready to Build Your Post-Settlement Advantage?

The landscape is shifting. The settlement creates opportunity, but only for pharmacies who act strategically right now. If you're looking for ways to diversify your sourcing and recover value from surplus inventory without depending on PBM generosity, RxPost connects you with other independent pharmacies solving this together.

Average pharmacy recovers $60,800 from surplus inventory in 60 days. That's real money that helps you invest in clinical services, staff better, and build the independent pharmacy future we're fighting for.

Get started on RxPost for free today and join the network of 700+ independent pharmacies building more predictable, more profitable, more patient-centered operations.